Alcon Q3 sales increase
Alcon has posted a net earnings of $446m for the third quarter 2010, or $1.47 per diluted share, compared to net earnings of $515m, or $1.71 per diluted
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.